Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
John E. Kao, Alignment Healthcare (ALHC) Chief Executive Officer and Director, reported multiple stock sales on 09/10/2025. The Form 4 shows three non-derivative disposition entries: 253,908 shares sold at a weighted-average price of $16.2293 (per-share range $15.74–$16.735), 101,110 shares sold at a weighted-average price of $16.8555 (per-share range $16.74–$17.24), and 180,000 shares sold under a Rule 10b5-1 plan at a weighted-average price of $16.4164 (per-share range $16.03–$16.73). The first two sales were to cover tax withholding on vested restricted stock units and are described as non-discretionary; the 180,000-share sale was executed under a pre-established 10b5-1 plan adopted 03/12/2025. Following the reported transactions, the filing indicates beneficial ownership figures of 4,634,678 shares, 4,533,568 shares, and an indirect holding of 1,193,100 shares through the JEK Trust (dated February 8, 2021) for which Mr. Kao is trustee.
Alignment Healthcare, Inc. (ALHC) Form 144 notifies a proposed sale of 430,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $7,086,400 and approximately 198,031,000 shares outstanding. The shares were acquired as restricted stock units on 03/25/2025. The filing lists the approximate sale date as 09/10/2025. The filing also discloses prior sales by JEK TRUST U/A DTD 02/08/2021 totaling 895,018 shares across June–September 2025 under 10b5-1 plans and direct sale, with listed gross proceeds for each sale. The notice includes required representations about material nonpublic information and 10b5-1 plan adoption language.
Alignment Healthcare, Inc. (ALHC) filing a Form 144 reports a proposed sale of 107,223 common shares through Morgan Stanley Smith Barney LLC on 09/10/2025 for an aggregate market value of $1,767,035.04, with the securities to be sold on NASDAQ. The shares were acquired as restricted stock units on 09/07/2025 and payment is recorded as N/A. The filing also discloses prior sales by Dawn Maroney: 108,439 shares on 09/08/2025 (gross proceeds $1,779,483.99) and three earlier 10b5-1 plan sales of 30,000 shares each on 08/13/2025, 07/14/2025, and 06/16/2025 with stated gross proceeds. The filer attests there is no undisclosed material adverse information.
Alignment Healthcare, Inc. is meeting with investors and analysts on September 9–10, 2025 to discuss its business strategy, competitive position in the Medicare Advantage market, and recent operating results. The company also plans to review preliminary Centers for Medicare & Medicaid Services Medicare Advantage Star ratings for rating year 2026 and payment year 2027.
Based on an early look at the data, Alignment Healthcare will reaffirm its expectation that approximately 100% of its membership will be enrolled in plans rated 4 Stars or higher, which is an important quality benchmark in Medicare Advantage. The company reminds readers that this expectation is forward-looking and subject to risks, including its ability to maintain high Star ratings, navigate regulatory requirements, manage provider relationships, and address labor and other operational challenges.
Alignment Healthcare, Inc. (ALHC) Form 144 notice reports a proposed sale of 25,000 common shares through broker Justin Tabit, with an aggregate market value of $423,750.00. The filing states the issuer has 198,031,417 shares outstanding and lists an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired on 10/06/2014 as a stock bonus from Joseph Konowiecki, and the original acquisition record shows 323,139 shares acquired with payment characterized as compensation. The filing also discloses a sale during the past three months: 25,000 shares sold on 07/31/2025 for gross proceeds of $398,750.00 by Joseph Konowi.
Form 144 notice for Alignment Healthcare, Inc. (ALHC) reports a proposed sale of 35,000 shares of common stock through E-Trade with an aggregate market value of $555,100, and an approximate sale date of 09/08/2025. The filing lists 198,031,417 shares outstanding. The securities to be sold were originally acquired as a stock award on 09/06/2023 under the issuer's 2021 Equity Incentive Plan, showing 61,256 shares acquired on that date. The filing also discloses prior sales under a 10b5-1 plan: 15,491 shares sold on 07/31/2025 for gross proceeds of $247,950.50. Other filer contact and CIK details are not provided in the document content.
Alignment Healthcare, Inc. (ALHC) filing a Form 144 notifies a proposed sale of 35,000 shares of common stock via E-Trade with an aggregate market value of $555,100, to be sold on 09/08/2025 on the Nasdaq Stock Market. The shares were acquired on 09/12/2022 from the vesting of restricted stock units under the company's 2021 Equity Incentive Plan. The filer also reported prior sales under a 10b5-1 plan on 06/10/2025 (60,000 shares, $876,048) and 06/11/2025 (40,863 shares, $621,207.50). The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Alignment Healthcare, Inc. (ALHC) filing a Form 144 notifies the proposed sale of 120,000 shares of common stock through E-Trade, with an aggregate market value of $1,903,200. The filer acquired the securities as restricted stock units that vested on 09/12/2022 (215,662 units granted under the 2021 Equity Incentive Plan). The filing reports recent Rule 10b5-1 plan sales by the same seller: three sales of 30,000 shares each on 06/16/2025, 07/14/2025, and 08/13/2025, generating gross proceeds of $434,280, $403,347, and $447,108 respectively. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Alignment Healthcare (ALHC) filed a Form 144 reporting a proposed sale of 380,000 shares of Common Stock through E-Trade, with an aggregate market value of $6,026,800 and an approximate sale date of 09/08/2025 on the Nasdaq Stock Market. The filer acquired 819,514 shares on 09/12/2022 via vesting of restricted stock units granted under the 2021 Equity Incentive Plan.
The filing also discloses recent sales executed under a Rule 10b5-1 plan by JEK Trust totaling 540,000 shares across four transactions in June–August 2025, with combined gross proceeds shown in the filing. The notice includes the standard signer representation about absence of undisclosed material adverse information.
Andreas P. Wagner, Chief Human Resources Officer at Alignment Healthcare, Inc. (ALHC), reported an insider sale. The Form 4 shows a sale of 12,032 shares of the company's common stock on 08/25/2025 at a price of $16.47 per share, leaving Mr. Wagner with 192,043 shares beneficially owned after the transaction. The filing indicates the sale was made pursuant to a Rule 10b5-1 trading plan adopted on 03/11/2025.